Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: D'Angelillo, Rolando M.; Franco, Pierfrancesco; De Bari, Berardino; Fiorentino, Alba; Arcangeli, Stefano; Alongi, Filippo
• Is Part Of: Critical reviews in oncology/hematology. Volume 93:Issue 2(2015)
• Page Start: 136
• Page End: 148
• Publication Date: 2015-02
• Subjects: Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2014.10.003
• Languages: English
• ISSNs: 1040-8428

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <p id="spar0005">Currently, androgen deprivation therapy (ADT) has a well-defined role when administered together with radiotherapy (RT): neo-adjuvant and concurrent combination for intermediate risk-disease and adjuvant therapy for high risk disease. Evidence of this association was generated by randomized trials designed and led approximately 30 years ago; thus the question which arises is how relevant and portable are these data in our current clinical practice?</p> <p id="spar0010">In the present review, we examine the pitfalls of these published randomized controlled trials, their relevance to present daily clinics, where high-dose external beam RT or brachytherapy is applied, as well as the adoption of ADT in patients with concomitant cardiovascular disorders.</p> </sec> </abstract>